Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Placental Congrong Runtong oral liquid is a Traditional Chinese Medicine (TCM) formulation developed by the Beijing Hospital of Traditional Chinese Medicine for the treatment of functional constipation, specifically the Yang-deficiency type. The formulation contains total glycosides of Cistanche extracted from *Cistanche deserticola* and placental extract (Placenta Hominis). In TCM theory, *Cistanche* tonifies the kidney and moistens the intestines, while the placental component addresses deep-seated systemic deficiencies. The drug aims to improve bowel movement frequency and stool consistency by addressing the underlying 'Yang deficiency' that leads to intestinal sluggishness. It is currently being evaluated in Phase II clinical trials to establish its safety, efficacy, and optimal dosing profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Placental Congrong Runtong oral liquid.